drugset / Trial / NCT07651748

Secretin in Ex-situ Liver Perfusion

NCT07651748

Phase 1/2 Enrolling by invitation 20 enrolled Erasmus Medical Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective is to assess whether the use of human synthetic secretin in a clinical (COR-)NMP procedure can restore physiological HCO3- content of the bile during ex-situ NMP.

Timeline

Start
2025-04-26
Primary completion
2026-06
Completion
2026-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Secretin Other / unclassified 16 ug Other

Indications

No indication recorded.